Last updated: February 20, 2026
What Is NDC 00069-1530?
NDC 00069-1530 corresponds to Hyaluronan (Hyaluronic Acid) injectable products used primarily in orthopedic and aesthetic indications. This NDC is linked to a specific formulation of hyaluronic acid intended for joint injections or dermal fillers.
Product Details and Market Position
| Attribute |
Specification |
| Manufacturer |
Allergan (AbbVie Inc.) |
| Formulation |
Hyaluronic acid, 20 mg/mL |
| Route of Administration |
Intrarticular (joint injections), subdermal (dermal fillers) |
| Indications |
Osteoarthritis knee pain, wrinkle correction |
The hyaluronic acid market has seen growth driven by an aging population, the rise in osteoarthritis cases, and increasing demand for minimally invasive cosmetic procedures.
Market Size
Global Hyaluronic Acid Market
- 2022 valuation: $8.3 billion (Grand View Research) [1]
- Projected CAGR (2023-2030): 8.2%
Orthopedic Segment
- 2022 revenue: ~$4.1 billion (EvaluatePharma) [2]
- Dominant players: Johnson & Johnson (e.g., Orthovisc), Genvisis, and Allergan.
Cosmetic Segment
- Market value: $4.2 billion (MarketsandMarkets) [3]
- Annual growth: Approx. 7%
Key Drivers
- Increased prevalence of osteoarthritis
- Usage in aesthetic dermatology
- Patent expirations of some formulations, leading to generics/competitors
Competitive Landscape
| Major Competitors |
Product Names |
Market Share (Est.) |
Key Features |
| Allergan |
Concepts, Juvéderm |
25% |
Established brand, broad indication |
| Merz |
Belotero |
12% |
Competitive pricing, high concentration |
| Teoxane |
RHA Collection |
10% |
Advanced formulations for dynamic wrinkles |
| Other |
Various |
53% |
Includes generics, regional brands |
Regulatory and Patent Status
- Patent protection for certain formulations ended in the late 2010s, increasing generic competition.
- FDA approvals for hyaluronic acid products continue to expand, with some formulations receiving new indications.
Price Projections
Current Pricing (U.S. Market)
- A typical dose (e.g., for knee injection): ~$600–$800 per treatment session.
- Dermal filler treatments: $600–$800 per syringe; full facial rejuvenation may require multiple syringes.
Historical Pricing Trends
| Year |
Average Price per Syringe |
Notes |
| 2018 |
~$750 |
Price maintained with minor fluctuations |
| 2020 |
~$720 |
Slight price reduction amid increasing competition |
| 2022 |
~$700 |
Competitive pressure intensifies |
Future Price Trends (2023–2027)
- Expected price decline: 2-4% annually due to increasing generic competition.
- Innovations and new indications may sustain prices in premium segments.
- Pricing differentiated by treatment setting: Higher prices possible for specialized formulations or FDA-approved branded products.
Factors Impacting Price Projections
- Patent expirations and entry of biosimilars.
- Market penetration of generics lowers overall pricing.
- Adoption of alternative therapies (e.g., platelet-rich plasma, stem cell therapy).
- Cost of manufacturing and interchangeability.
Revenue and Profitability Estimates
| Assumption |
Details |
| Annual unit sales |
2 million syringes (globally) by 2027 |
| Average price per syringe |
$700 (declining trend) |
| Market share |
20-25% in target indications |
Estimated revenue for NDC 00069-1530 could reach $1.4–$1.75 billion globally in 2027, assuming aggressive market share and volume growth.
Key Market Risks
- Patent expirations and biosimilar entry.
- Regulatory challenges in emerging markets.
- Competition from non-invasive or alternative therapies.
- Pricing pressures in payor negotiations.
Summary
NDC 00069-1530 operates in a mature, competitive hyaluronic acid market experiencing steady growth. The pricing landscape is under pressure from patent losses and patent challenges. Revenue projections suggest a gradual decline in per-unit pricing, but volume growth and new indications could offset price erosion to sustain overall revenues in the billion-dollar range.
Key Takeaways
- The hyaluronic acid market is growing at approximately 8% annually.
- Current price per syringe averages around $700, with slight regional variations.
- Competitive pressure is expected to trigger a 2-4% annual price decline.
- Revenue in 2027 could approximate $1.5 billion worldwide, driven by increased adoption.
- Patent expirations and biosimilar entries pose key risks.
FAQs
1. How will patent expirations affect the pricing of NDC 00069-1530?
Patent expirations typically lead to increased generic competition, driving prices downward and reducing profit margins unless the brand maintains differentiation or secures new patents.
2. What are the primary indications influencing market demand?
Osteoarthritis knee injections and dermal fillers constitute the primary demand drivers, with aging populations and cosmetic procedures expanding markets.
3. How does reimbursement impact pricing strategies?
Reimbursement policies favor cost-effective treatments, pressuring brands to lower prices or demonstrate added value for premium pricing.
4. Are biosimilars entering the hyaluronic acid market?
Yes, biosimilar development is progressing, which could significantly impact pricing and market share within the next 3–5 years.
5. What technological or formulation innovations could sustain pricing?
Advances such as cross-linked formulations with longer duration, or formulations with added therapeutic effects, could sustain or raise prices.
References
[1] Grand View Research. (2022). Hyaluronic Acid Market Size, Share & Trends Report.
[2] EvaluatePharma. (2022). Osteoarthritis Market Analysis.
[3] MarketsandMarkets. (2022). Aesthetic and Dermatology Market Trends.
(Note: Specific references are based on industry reports as of 2022; actual figures may vary.)
